Eribulin in advanced breast cancer: safety, efficacy and new perspectives

被引：9
|
作者：
Garrone, Ornella [1 ]
Miraglio, Emanuela [1 ]
Vandone, Anna Maria [1 ]
Vanella, Paola [1 ]
Lingua, Daniele [1 ]
Merlano, Marco C. [1 ]
机构：
[1] Med Oncol AOS Croce & Carle Osped Insegnamento, Cuneo, Italy
来源：
FUTURE ONCOLOGY | 2017年 / 13卷 / 30期
关键词：
chemotherapy; eribulin; mechanism of action; metastatic breast cancer; new treatment; HALICHONDRIN-B ANALOG; ADVANCED SOLID TUMORS; PHASE-I; LOCALLY RECURRENT; 1ST-LINE THERAPY; CONSORTIUM TRIAL; DOSE-ESCALATION; POOLED ANALYSIS; MESYLATE E7389; CHEMOTHERAPY;
D O I：
10.2217/fon-2017-0283
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Eribulin is a synthetic analog of halichondrin B belonging to microtubule-targeted agents with a distinct mechanism of inhibition of microtubule dynamics. This molecule has multiple nonmitotic effects on tumor biology, exhibiting effects on epithelial-mesenchimal transition and tumor vasculature. We review here preclinical and clinical studies on eribulin. The mitotic and nonmitotic effects together with its favorable safety profile make eribulin a unique drug with high potential in the treatment of metastatic breast cancer. The new emphasis of eribulin mechanism of action on vascular remodeling, microenvironment modifications and reversal of epithelial-mesenchimal transition paves the way to rethinking the use of the drug in an immunological perspective.
引用
收藏
页码：2759 / 2769
页数：11
相关论文
共 50 条
  • [31] Efficacy and safety of eribulin in real life in the treatment of metastasic breast cancer in a Spanish general center
    Ruiz, Ignacio Patier
    Peiro, Juan Francisco Marquez
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2022, 35 (04): : 221 - 227
  • [32] EFFICACY AND SAFETY OF ERIBULIN IN PATIENTS WITH TRIPLE NEGATIVE METASTATIC BREAST CANCER: REAL LIFE EXPERIENCE
    Valentinova, Ludmila Manzyuk
    BREAST, 2017, 36 : S57 - S58
  • [33] Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience
    Lutrino, Eufemia S.
    Orlando, Laura
    Febbraro, Antonio
    Giampaglia, Mariangela
    Zamagni, Claudio
    Schiavone, Paola
    Scavelli, Claudio
    Dima, Gianluca
    Fedele, Palma
    Giordano, Guido
    Bilancia, Domenico
    Quaranta, Anna Maria
    Rubino, Daniela
    Filippelli, Gianfranco
    Fontanella, Caterina
    Caliolo, Chiara
    Marino, Antonella
    Calvani, Nicola
    Ferrara, Pasqualinda
    Cinieri, Saverio
    TUMORI JOURNAL, 2020, 106 (04): : 301 - 305
  • [34] Efficacy and safety of eribulin in patients with triple negative metastatic breast cancer: real life experience
    Manikhas, A.
    Gorbunova, V.
    Manzyuk, L.
    Kovalenko, E.
    Bolotina, L.
    Zhukova, L.
    Vladimirova, L.
    Kolyadina, I.
    Ponomarenko, D.
    Mukhametshina, G.
    BREAST, 2019, 44 : S61 - S62
  • [35] Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer
    Coyne, Geraldine O'Sullivan
    Walsh, Janice
    Kelly, Catherine M.
    EXPERT OPINION ON DRUG SAFETY, 2012, 11 (04) : 643 - 650
  • [36] Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer
    Cortes, Javier
    Lorca, Rebeca
    FUTURE ONCOLOGY, 2011, 7 (03) : 355 - 364
  • [37] Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis
    Tanni, Kaniz Afroz
    Truong, Cong Bang
    Johnson, Brandon S.
    Qian, Jingjing
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 163
  • [38] Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes
    Maeda, Shigeto
    Saimura, Michiyo
    Minami, Shigeki
    Kurashita, Kaname
    Nishimura, Reiki
    Kai, Yuichiro
    Yano, Hiroshi
    Mashino, Kohjiro
    Mitsuyama, Shoshu
    Shimokawa, Mototsugu
    Tamura, Kazuo
    BREAST, 2017, 32 : 66 - 72
  • [39] Neutrophil to lymphocyte ratio (NLR) may predict survival and efficacy of eribulin in advanced breast cancer patients
    Haruyama, Y.
    Fukuma, E.
    Yu, O.
    Koshida, Y.
    Sakamoto, N.
    Gen, A.
    Nakagawa, R.
    Nashimoto, M.
    Sakamoto, M.
    Teraoka, K.
    Nakagawa, M.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S64 - S65
  • [40] EFFICACY AND SAFETY OF ERIBULIN COMPARED WITH CONTROL THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Pagada, A.
    Mishra, R. K.
    Bolshete, P.
    Rai, M. K.
    VALUE IN HEALTH, 2018, 21 : S10 - S10
12345